Checkpoint kinase 1 (Chk1), a serine/threonine kinase, plays an important role in DNA damage checkpoint control and is an attractive target for cancer treatment. To develop a Chk1-specific cell-based assay, stable clones were established in which Chk1 kinase domain fused at its N-terminus with p53 through 4 tandem repeats of Gly-Gly-Gly-Gly-Ser was expressed in an inducible manner. Chk1 kinase specificity of the phosphorylation of fused p53 was confirmed by the experiments with a kinase-inactive Chk1. Only in the presence of an inducer molecule was phosphorylation of p53 at Ser-15 in the stable clones induced. Furthermore, its assay performance proved acceptable for high-throughput screening applications, judging from the Z′ factor values (> 0.77). Finally, the cell-based assay thus established yielded structure-activity relationship data for a small set of test inhibitors of Chk1 within cells. Collectively, these results demonstrate that the established cell-based assay provides a novel and highly sensitive cellular platform for Chk1 inhibitor discovery. (Journal of Biomolecular Screening 2007:809-817) 
INTRODUCTION
C HECKPOINT KINASE 1 (CHK1) is an evolutionarily conserved serine-threonine kinase that plays an important role in the DNA damage response and was originally identified as a kinase that regulates the G2/M checkpoint. 1 For therapeutic cancer intervention, a combination treatment with checkpoint inhibitors and either DNA-damaging drugs or irradiation has been proposed as a way to enhance the efficacy of monotherapy, and this strategy has shown positive results in various cell culture cancer models. 2, 3 UCN-01, a potent Chk1 inhibitor, is undergoing clinical trials as a kinase inhibitor for cancer treatment. 4 Tumor suppressor protein p53 is one of the authentic substrates of Chk1, which phosphorylates p53 at Ser-15, Thr-18, Ser-20, and Ser-37 in its N-terminal domain. 5 Under physiological conditions, p53 associates with MDM2 protein, the E3 ubiquitin ligase that mediates ubiquitination and rapid degradation of p53 by the 26S proteosome. [6] [7] [8] However, when cells are exposed to DNA damage, nitric oxide, hypoxic conditions, or other cellular stress, p53 is phosphorylated and increases its stability via decreasing its affinity toward MDM28: Phosphorylation on p53 at serine 15 and serine 20 are indeed located within or close to the MDM2 binding sites (threonine 18 and serine 20) of p53. 9 To identify cell-active Chk1 kinase inhibitors, it is vital to develop a cell-based assay that could allow determination of compounds' structure-activity relationship in a target-specific manner. Two major approaches have been used to develop cell-based assays for kinase inhibitors: One is to evaluate proximal effects of the target kinase inhibition, and the other is to monitor more distal effects of the kinase activity (e.g., calcium mobilization 10 or reporter gene response 11 ), as an indication of specific pathway activation. Although proximal effects of kinase inhibition can be determined by autophosphorylation assays for tyrosine kinases, 12 only a few reports have been published so far on monitoring those for serine/threonine kinases, most of which are unable to phosphorylate themselves. Thus, development of target-specific, cellbased screening assays for serine/threonine kinases is critical.
Fusion protein constructs, such as green fluorescent proteinand tag-labeled protein, serve in assays for monitoring localization of target proteins within living cells, 13 and antibody fusion proteins also serve to direct transport of fused reagents to the antibody's targets localized in cell membranes or internal organs. 14 In addition, fusion proteins have been used to prepare constitutively active mutant kinases, such as TAK1 15 and JNK1/3. 16, 17 In the latter case, the upstream kinase, JNK-activating kinase (JNKK1 and JNKK2), was fused to JNK1/3 to fully activate the kinase via phosphorylation at 2 specific residues in JNK1/3. These experiments suggest that a serine/threonine kinase, when it is linked to an appropriate substrate through a flexible linker, can induce phosphorylation of the linked substrate.
This report was designed to develop a robust cell-based assay for discovery of Chk1 specific drug candidates. We established stable clones in which the Chk1 kinase domain fused at its N-terminus with p53 through 4 tandem repeats of Gly-Gly-Gly-Gly-Ser was expressed in an inducible manner. The results indicate that the stable clones serve as a high-throughput, robust, and highly sensitive cellular screening for Chk1 kinase inhibitors.
MATERIALS AND METHODS

Materials
Staurosporine was purchased from Sigma (St. Louis, MO). Other test inhibitors were originally synthesized by GlaxoSmithKline (Brentford, UK). The p53 monoclonal antibody (clone 80, #BD-610180) was purchased from Becton Dickinson Biosciences (San Jose, CA), anti-hemagglutinin (HA) monoclonal antibody (12CA5) from Roche Diagnostics (Basel, Switzerland), and anti-phospho-p53 (Ser-15) polyclonal antibody (#9284L) and antirabbit IgG-HRP antibody (#7071-1) from Cell Signaling Technology (Beverly, MA). Antimouse IgG-HRP antibody was purchased from DAKO (Glostrup, Denmark).
Expression plasmids
A cDNA fragment encoding a p53 polypeptide with the repeated HA tag (2HA) at the N-terminus and the GS (Gly-Gly-Gly-Gly-Ser) 4 linker 18 at the C-terminus was generated by PCR using cDNA prepared from HeLa cells. This fragment, which contained an N-terminus Kpn1 site and a C-terminus Spe1 site, was cloned into the pGene/V5-His vector (Invitrogen, Madison, WI) previously digested with Kpn1 and Spe1. The resulting vector, pGene-2HA-p53-GS, which contained a Spe1 site at the C-terminus of the GS linker, was ligated with the following 2 kinase constructs digested with Nhe1 enzyme. cDNA encoding the Chk1 construct was amplified by PCR using cDNA of the generous gift from Dr. Bing-Bing S. Zhou (Incyte Genomics Inc., Newark, DE) and cloned into pGene-2HA-p53-GS to generate 2HA-p53-GS-Chk1KD(1-270; kinase domain). This construct was sequenced, revealing a sequence identical to that deposited under the NCBI accession number NM_001274. The other construct, a catalytically inactive Chk1 derivative construct containing alanine in place of aspartate at amino acid 148 in the adenosine triphosphate (ATP)-binding site (Chk1 D148A), was prepared using the QuickChange™ system (Stratagene, La Jolla, CA), and the substitution was also verified.
Cell cultures and preparation of stably regulatory expressed cell lines
The 3T3pGeneSwitch™ cell line (Invitrogen), which stably expresses the Ga14-DBD/hPR-LBD/p65-AD fusion gene, was cultured using Dulbecco's modified Eagle's medium (DMEM; Sigma, Poole, Dorset, UK) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin G, 100 µg/mL streptomycin sulfate (GIBCO BRL, Rockville, MD), and 50 µg/mL hygromycin (Invitrogen) to maintain the fusion gene.
For the generation of cell lines with a stably integrated p53 fusion kinase gene, 3T3pGeneSwitch™ cells were transfected by standard calcium phosphate procedure (Invitrogen). Cells were grown and selected in DMEM with 10% FBS containing 300 µg/mL Zeocin (Invitrogen). After 2 to 3 weeks, individual antibiotic-resistant clones were extracted and protein expression analyzed with both Western blots and enzyme-linked immunosorbent assay (ELISA). Stable cell lines were maintained with 10% FBS containing 50 µg/mL hygromycin and 300 µg/mL Zeocin.
Preparation of both transient transfectant and stable cell lines for compound screening
For the preparation of transiently transfected cells for compound screening, 75 µL of 3T3pGeneSwitch™ cells, at 2 × 10 4 cells per well, were seeded into 96-well plates and then cultured in DMEM supplemented with 10% FBS and 50 µg/mL of hygromycin at 37 °C. After a 7-h incubation, the cells were transfected with 25 µL of expression plasmid encoding the appropriate p53-kinase fusion protein using Fugene6 reagents (Roche Diagnostics) for 20 h according to the manufacturer's protocol. For the GeneSwitch cell lines stably integrated with a p53 fusion kinase gene, 100 µL of the cells, at 5 × 10 4 cells per well, were seeded into 96-well plates. These cells then were cultured overnight in DMEM supplemented with 10% FBS at 37 °C.
After incubation, the culture medium was changed to 100 µL of mifepristone containing 10% FBS media at a final concentration of 1 × 10 -8 M and incubated for 4, 6, 9, or 24 h, depending on the experiment. The cells were then treated with various concentrations of test compound in the presence of 10% FBS for the final 1 or 2 h of mifepristone induction, depending on the experiment. Culture plates were placed on ice, and the cells were lysed with 100 µL per well of cold lysis buffer (137 mM NaCl, 2 mM EDTA, 10% glycerol, 1% TritonX-100, 20 mM Tris-HCl [pH 8.0], and 1 mM sodium orthovanadate). The lysis solutions were transferred to an ELISA plate or analyzed with immunoblot assay (described below).
Immunoblot analysis
Samples of lysed cell extracts were resolved by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ) for 1 h at 100 V. The filters then were blocked with 5% skim milk in 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween-20 (TBST) for 1 h. For Western blot analysis, anti-phospho-p53 (Ser-15) antibody, anti-pan-p53 antibody, and anti-HA antibody were used. Primary anti-phospho-p53 (Ser-15) and anti-pan-p53 antibodies were diluted 1:1000 in TBST containing 5% bovine serum albumin or 5% skim milk, respectively. Anti-HA antibody was diluted 1:4000 in TBST containing 5% skim milk. Blotted membranes were incubated with these antibodies at 4 °C overnight. The membranes then were washed 3 times with 20 mL of TBST before appropriate secondary antibodies were added. Goat antirabbit IgG HRP conjugate, for detecting anti-phospho-p53 (Ser-15) antibody, was diluted 1:2000 in TBST containing 5% skim milk. Goat anti-mouse IgG HRP conjugate, for detecting both anti-pan-p53 antibody and anti-HA antibody, was diluted 1:1500 in TBST containing 5% skim milk. The secondary antibodies were added to the membranes, followed by 1 h incubation at room temperature. The membranes then were washed 4 times in TBST, and bound antibodies were visualized with enhanced chemiluminescence reagents (Amersham Biosciences).
ELISA procedure
Flat-bottom, high-capacity ELISA plates (Corning, Acton, MA) were coated with 100 µL of monoclonal anti-HA antibody in phosphate-buffered saline (PBS; +) at 250 ng per well and incubated overnight at 4 °C. Plates were then blocked with 200 µL of 0.05% Tween-20 in PBS (PBST; Sigma) containing 5% skim milk for 2 h. Medium was aspirated, and plates were rinsed once with 200 µL of PBST. Cell lysate was added to each well, and the plates were incubated at 4 °C overnight. Cell lysates then were removed and the plates washed 3 times with 200 µL of PBST. After washing, 100 µL of 1:1000 diluted antiphospho-p53 (Ser-15) antibody in PBST containing 5% skim milk was added to each well, followed by incubation at room temperature for 1 h. Wells were again washed 3 times with 200 µL of PBST. Goat anti-rabbit IgG antibody HRP conjugate diluted 1:1000 in PBST containing 5% skim milk was then added to each well, followed by incubation for 1 h at room temperature. Finally, the medium was aspirated and plates rinsed 4 times with 200 µL of PBST. A total of 100 µL of TMB substrate solution (Pierce Biotechnology, Rockford, IL) was added to each well, and the plates were incubated for about 10 min. The reactions were stopped by adding 100 µL of 2 M H 2 SO 4 to each well and absorbance at 450 nm measured with a 1420 Multilabel Counter (PerkinElmer, Boston, MA).
Percentage inhibition was calculated from the ELISA assay signal intensity by using the formula
where A is induction, B is noninduction, and X is the test compound.
The IC 50 value was calculated by fitting the data to the Hill equation using a nonlinear least-squares curve-fitting with Marquardt-Levenberg algorithm. 19 
In vitro Chk1 assay
Scintillation proximity assay (SPA) technology was used for detection of Chk1 kinase activity in vitro. Chk1 kinase domain (residues 1-289) with 6XHis tag was expressed in baculovirusinfected Sf9 cells and purified on Ni-charged nitriloacetic acid agarose affinity columns. The purified enzyme was stored in 25 mM HEPES, pH 7.5, 0.5 M NaCl, 10% glycerol, 0.05% octylglucoside, 5 mM DTT, and 1 mM EDTA. Chk1 protein kinase is known to phosphorylate BRCA1. 20 
RESULTS
Construction of p53-Chk1 fusion proteins with the GeneSwitch system
To specifically monitor the cellular catalytic activity of Chk1, the kinase domain of Chk1 was fused to wild-type p53 via a GS linker, which has 4 tandem Gly-Gly-Gly-Gly-Ser repeats. The GS linker situated between the full-length p53 tumor suppressor and Chk1 ensured that both p53 and Chk1 proteins are flexibly interacted. Fusion constructs were inserted into the GeneSwitch vector to control conditional protein expression ( Fig. 1) . Moreover, the repeated hemagglutinin tag (2HA) was introduced into the N-terminal of each fusion construct to specifically capture the p53-Chk1 fusion proteins in the ELISA system. We designed and constructed the pGene-2HA-p53-GS vector to be a cassette vector for easy substitution of other kinase domains. This design enabled us to easily insert the catalytically inactive Chk1 derivative into the vector as a Screening Method for Cell-Active Chk1 Inhibitors control fusion construct to verify the feasibility of the p53-Chk1 fusion system.
Expression and phosphorylation of p53-Chk1 fusion protein under GeneSwitch regulation
After a 4-h induction by mifepristone, expression and phosphorylation of p53-Chk1 fusion proteins became detectable in Western blots with anti-HA and anti-phospho-p53 (Ser-15) antibodies, respectively ( Fig. 2) . However, essentially no p53 phosphorylation was observed for the kinase-inactive Chk1 (D148A) construct ( Fig. 2A) . These results suggested that the phosphorylation level of the p53-Chk1 fusion protein was highly dependent on the catalytic activity of the fused kinases and that the GeneSwitch system was suitable for controlling the conditional protein expression. The expression level of the p53-D148A Chk1 was much lower compared with the level of wild-type Chk1 (Fig. 2B) . Interestingly, the observed correlation here between the phosphorylation and expression levels of the fused p53-Chk1 proteins was also seen for experiments using the constitutively expressed form of p53-Chk1 proteins, described in our previous study. 21 This evidence indicated that the total expression level of p53-Chk1 proteins was strictly regulated by the p53 modification via phosphorylation.
Optimization of experimental conditions
The optimal conditions of mifepristone-induced regulatory expression of p53-Chk1 proteins were determined by time-course study. After a 4-h induction by mifepristone, the phosphorylation of the fused p53 was detectable with Western blotting, and the phosphorylation subsequently increased in a time-dependent manner ( Fig. 3A) . Similar to the change in phosphorylation level, the expression of the fusion protein, which was detected by both anti-pan-p53 and anti-HA antibodies, also increased ( Fig. 3B, C) . Through this time-course experiment, we concluded that it is possible to detect the remarkable phosphorylation of the p53 fusion proteins after a 4-h induction by mifepristone.
Next, test compound staurosporine, a potent Chk1 inhibitor, 22 was used as a validation tool to confirm whether the system could monitor the compound's inhibitory activity through the detection of phosphorylation in fused p53 proteins (Fig. 4) . During 6-, 9-, and 24-h stimulation, the cells were treated with 0.5 µM of staurosporine for either 1 or 2 h before cell destruction for analysis. As a result, the phosphorylation of the p53 fusion protein was significantly inhibited for both time points of compound treatment, with 2-h treatment showing higher inhibitory activity. No significant difference in the inhibitory activity of staurosporine between 6 and 9 h of mifepristone stimulation was observed. However, staurosporine exhibited less inhibitory activity for 24-h mifepristone stimulation compared with the other 2 induction states. Based on this result, we concluded that the shorter periods of both mifepristone stimulation and compound treatment were appropriate for establishing a more sensitive assay capable of assessing inhibitory compound efficacy but in which the toxicity effect of the inhibitory compounds is reduced. To further validate the assay system, we therefore selected the experimental condition of treating the 3T3pGeneSwitch™ cells with test compounds for the final hour of a 6-h mifepristone induction.
Evaluation of the IC 50 of test compounds by the p53-Chk1 fusion system
We changed the detection format from Western blot to ELISA to quantitatively determine the potency of kinase inhibitors. The assay was evaluated with 2 kinds of test compounds: low-and high-potency kinase inhibitors in the Chk1 enzyme assay. As shown in Figure 5A SB-386023, 24 a low-potency inhibitor in the SPA assay (IC 50 >10 µM), did not show any inhibitory activity in this cell-based assay (Fig. 5B) . These results show that the fusion system could provide quantitative data for Chk1 inhibition by test compounds.
To further evaluate the fusion assay, the total amount of the p53 fusion protein was estimated with anti-pan-p53 antibody concurrently with the phosphorylation. Although the total expression of the p53-Chk1 fusion protein in SB-386023-treated samples was not influenced by treatment, the expression level within cells treated with SB-734455-M showed a declining trend that was similar to that observed for the phosphorylation (Fig. 5A, B) . This result also suggests that the phosphorylation state of p53 might be closely related to the total amount of fusion protein expressed.
Generation of stable clones and feasibility study for compound screening
To further establish a robust and high-throughput compoundscreening system, stable clones containing regulatory expressed p53-Chk1 proteins were generated with 3T3pGeneSwitch™ cells using a standard calcium phosphate procedure. Twenty-four clones were selected for further analysis using Western blotting to confirm the phosphorylation level of p53-Chk1 proteins. After a 6-h mifepristone induction, 11 clones showed a significant level of p53 phosphorylation in greater or lesser extent within each clone (Fig. 6A) . Among the obtained stable clones, the 4 representative clones (20, 26, 35, 59) were picked up randomly by covering the divergent phosphorylation level of each clone, and they were further evaluated by comparing them with transient transfectants against the following factors: signal to background ratio (S/B ratio), Z′ factor, and efficacy of test compounds. These 4 clones showed high Z′ values (0.77-0.89), indicating acceptable quality for high-throughput screening (HTS). 25 Every clone also demonstrated a 10-to 15-fold S/B ratio. Moreover, 2 test compounds (SB-715515 and SB-723689-A) identified by in vitro enzyme assay exhibited similar inhibitory activity for all 4 clones, with consistent IC 50 values. As a whole, these selected stable clones showed comparable results to those of the transient transfection method (Fig. 6B) .
Within the prominent 4 clones, we selected clone 20 based on its high S/B ratio and Z′ factor in actual screening and its sensitivity to test compounds. Moreover, this clone was competent to robust screening, with stable proliferation and no morphological change during long-term cultivation in comparison with clone 59. By using clone 20, we further evaluated the robustness and reproducibility of this platform with 3 independent runs. As shown in Figure 6C , clone 20 showed a sufficient S/B ratio (>14.5), high Z′ factor (>0.87), and good reproducibility on the IC 50 values of SB-723689-A. These numbers are sufficient to conduct robust HTS against a large library containing a large number of compounds. In the following experiments, the assay was conducted using clone 20 to evaluate compound efficacies.
Validation of p53-Chk1 fusion system with test compounds
The p53-Chk1 fusion assay was further validated with a variety of test inhibitors. Those test compounds were selected based on a high-throughput screening of a compound library with an in vitro enzyme assay (SPA), and a wide range of inhibition of Chk1 activity was observed. Table 1 shows the data obtained using 2 different assays, an in vitro enzyme, and the p53 fusion cellular assay. In Table 1 , test compounds were put in order of increasing inhibitory activity determined with the in vitro kinase assay.
SB-734455-M, which shows the most potent of inhibition of Chk1 kinase activity in the in vitro enzyme assay (SPA; IC 50 = 0.01 µM), also showed the most potent inhibitory activity in the p53-Chk1 fusion assay (IC 50 = 0.03 µM). Furthermore, the weak compounds, SB-715109 and SB-386023 (SPA; IC 50 > 10 µM), did not show any inhibitory activity in the p53-Chk1 fusion assay even up to 30 µM. The fusion cellular system could clearly distinguish the 2 orders difference in IC 50 values, from 0.01 µM to 1.17 µM, observed with the in vitro kinase assay. In 1 case (SB-715938), the compound ranked in the 3rd position of inhibitory potency in the in vitro enzyme assay, but its rank order in the p53-Chk1 assay was 5th. Differences in rank order between the in vitro and cellular assay might be caused by differences in a compound's physicochemical properties (e.g., solubility or cell permeability) in the 2 assay systems. These results suggest that the p53 fusion system could, in most cases, yield the accurate rank order of the inhibitory activity of screened compounds against Chk1 kinase in cells with high sensitivity.
DISCUSSION
A Chk1-specific cellular assay was established in which the Chk1 kinase domain linked to the tumor suppressor protein p53 via a flexible linker was conditionally expressed in stable clones. Chk1 kinase specificity of the phosphorylation of fused p53 was confirmed by the experiments with a kinase-inactive Chk1. The Chk1-p53 fusion molecules were captured with anti-HA antibody in ELISA via the repeated hemagglutinin tag (2HA) introduced into the N-terminus of the fusion construct independent to endogenously expressed p53 proteins. The performance of the assay proved acceptable for robust screening applications, judging from the observed Z′ factor values (>0.77).
Previous reports demonstrated that a fusion protein can be prepared to make constitutively active JNK1/3. 16, 17 For example, when JNK1/3 was fused with its upstream kinase, JNK-activating kinase (JNKK1 and JNKK2), the fused JNK1/3 became fully active via phosphorylation at 2 specific threonine and tyrosine residues in JNK1/3. These studies suggested that the specific activity of targeted kinases could be monitored by bringing those kinases and substrates into close proximity.
In our fusion construct, the GS linker, which has the feature of 4 tandem repeats of Gly-Gly-Gly-Gly-Ser, was inserted into the space between the full-length p53 tumor suppressor protein and Chk1 to maintain stereotypic flexibility of the fusion proteins. Moreover, the double HA tag was introduced into the Nterminus of fusion construct to enable selective capture of the recombinant p53 proteins from endogenous p53 expressed by cells. By using an anti-HA antibody as a capture antibody, we could efficiently detect the phosphorylation level of p53 fusion protein independent to endogenous p53 proteins, yielding S/B ratios of more than 10, which was sufficient for compound screening (Fig. 6B, C) .
To achieve better throughput and reproducibility of the assay, experiments were designed to establish stable p53-Chk1-expressing clones. First, we adopted the vector construct that allowed constitutive expression of the p53 fusion proteins. However, all clones thus obtained were apt to grow slowly and finally entered cell death. Although several articles reported failure to maintain overexpression of wild-type p53 within cells, stable p53-expression clones were obtainable when p53-induced cell apoptosis was avoided by introducing mutations in p53 molecules. 13 Therefore, at our 2nd attempt, we made several mutated p53 proteins and conjugated them with Chk1 via the GS linker. In our hands, none of the clones established constitutively expressed the mutated p53 proteins. In our final attempt, the GeneSwitch transcriptional control system 25 was introduced to make stable cell lines, in which the p53 fusion protein could be regulatorily expressed by the addition of a specific inducer, mifepristone. From a total of 24 clones tested, we established 11 clones that stably carried the p53-Chk1 construct gene, all of which proved able to induce significant phosphorylation of p53 in the fusion protein 6 h after mifepristone induction (Fig. 6A) . Those clones proved stable enough to be maintained over 30 passages without significant loss in inducible expression of the p53-Chk1 gene (data not shown). This system could achieve robust and quantitative HTS with stable clones and successfully distinguish 2 orders difference in IC 50 values of test compounds, from 0.01 µM to 1.17 µM, obtained with an in vitro kinase assay. Moreover, the system generally yielded the correct rank order of inhibitory activity for the assessed compounds against cellular Chk1 kinase ( Table 1 ). In addition, the correlation coefficient for IC 50 values between our cell-based assay and enzyme assay demonstrated a close interrelation (r = 0.892). Although there is good correlation between our cellular assay and the in vitro enzyme assay, the IC 50 values in the cell-based assay were almost 2 to 20 times less potent than that of the in vitro enzyme assay. For reversible and ATP competitive inhibitors, IC 50 values were calculated from the formula IC 50 = Ki (1 + [ATP]/K M, ATP ). 27 This formula indicates that the IC 50 values largely depend on the ATP concentration and K M, ATP . Within cells, the ATP concentration is reported as 1 to 5 mM, so the difference of ATP concentration between the cell-based assay and the in vitro enzyme assay is estimated at almost 1000-fold. 28 Moreover, K M, ATP is affected by the type of substrates used in the kinase reaction, in which the p53 protein and BRCA1-derived peptide were used for cell and in vitro enzyme screens, respectively. Therefore, the dissociation of IC 50 values between the cellular and enzyme assay might be due to the different ATP concentrations and different substrates for Chk1 between each platform.
The p53 stability is regulated by the rapid degradation via the ubiquitin-proteasome pathway, although a role for other proteolytic enzymes such as calpain may also be involved. 29 It is well known that both the activity and expression level of the p53 protein are regulated through the phosphorylation-dependent stabilization of p53 when cells are exposed to DNA damage, nitric oxide, hypoxic conditions, or other cellular stress. 8, 9 In fact, when p53 was fused with kinase-inactive Chk1, phosphorylation of the fused p53 protein was not observed, and the total amount of fusion protein was fairly low (Fig. 2) . Moreover, the Chk1 inhibitor SB-734455-M reduced the total amount of p53 fusion protein in a dose-dependent manner, as it inhibited the phosphorylation of the p53 fusion protein (Fig. 5A) . Major mechanisms for controlling p53 stability are its interaction with the MDM2 protein, which binds to a region of the transactivation domain of p53 and blocks the downstream signal communication, 30 and MDM2-mediated ubiquitination of p53 proteins, which causes their rapid turnover by transporting them to the 26S proteosome. 6, 7 The affinity between p53 and MDM2 is reduced through the phosphorylation of p53 at the MDM2 binding sites. 8 Key phosphorylation sites are serine 15 and serine 20 on the p53 protein, which are located within or close to the MDM2 binding site (threonine 18 and serine 20). 9 These biological aspects of p53 proteins were consistent with our results for the relationship between the phosphorylation level and the degree of p53 stability.
Finally, potentiality of further technical improvements should be discussed for automatable and miniaturizable operation of our Chk1 assay. Although ELISA demonstrated a high S/B ratio (about 15), Z′ factor (> 0.87), and highly reproducible IC 50 evaluations for tool inhibitors, homogeneous readout is ideal for robust HTS of complex cell-based assays. As shown in this report, phosphorylation of our surrogate substrate p53 is easily and specifically detectable by 2 different antibodies against the serine 15 residue in p53 protein and HA epitope at N-terminus of fusion protein. We preliminarily demonstrated that homogenous detection of p53 phosphorylation in a 384-well format could be achievable by using AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay; PerkinElmer), in which only mixing of anti-HA acceptor beads, biotinylated phospho-p53 antibody, and streptavidin donor beads with cell lysates results in signal production by using the close proximity between donor and acceptor beads (data not shown).
In summary, we established a high-throughput, robust, and highly-sensitive screening for cellular active Chk1 inhibitors. Regulatory expression of p53-Chk1 proteins allows the establishment of the necessary stable clones that exhibit good assay performance with a high S/B ratio and reliable Z′ factors. Considering the universal utility of p53 as a substrate for diverse classes of serine/threonine kinases in the p53 fusion system, 21 the p53 system may provide an invaluable platform for drug discovery approaches in the kinase research area.
